| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
35,285 |
29,683 |
$1.67M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
44,949 |
40,762 |
$1.41M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
31,244 |
24,292 |
$878K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
11,237 |
10,568 |
$491K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
5,707 |
5,427 |
$448K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,907 |
3,352 |
$285K |
| 64635 |
|
1,612 |
1,087 |
$179K |
| 64493 |
|
2,712 |
1,735 |
$166K |
| 62323 |
|
1,988 |
1,406 |
$112K |
| 64494 |
|
2,661 |
1,712 |
$87K |
| 64636 |
|
1,638 |
1,082 |
$77K |
| 95886 |
|
646 |
563 |
$57K |
| 80361 |
|
5,382 |
4,986 |
$55K |
| 95913 |
|
318 |
274 |
$44K |
| 64495 |
|
1,114 |
647 |
$19K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
4,894 |
4,488 |
$19K |
| 95912 |
|
111 |
107 |
$17K |
| 80365 |
|
1,609 |
1,470 |
$14K |
| 64490 |
|
86 |
53 |
$5K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,920 |
1,244 |
$3K |
| 64491 |
|
87 |
53 |
$3K |
| 64633 |
|
52 |
25 |
$3K |
| 99406 |
|
230 |
203 |
$2K |
| 27096 |
|
36 |
26 |
$1K |
| 80355 |
|
138 |
122 |
$1K |
| 80373 |
|
474 |
426 |
$1K |
| 64634 |
|
53 |
25 |
$1K |
| 62321 |
|
19 |
12 |
$1K |
| 62370 |
|
21 |
12 |
$705.49 |
| 99442 |
|
85 |
36 |
$523.60 |
| 20553 |
|
12 |
12 |
$286.03 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
32 |
26 |
$279.48 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,252 |
770 |
$60.79 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
42 |
41 |
$45.94 |
| 80354 |
|
83 |
67 |
$15.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
10,366 |
9,006 |
$0.00 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
10,333 |
8,996 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
10,810 |
9,373 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
7,502 |
6,521 |
$0.00 |
| 1124F |
|
6,269 |
5,537 |
$0.00 |
| 4004F |
|
2,869 |
2,506 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
10,270 |
8,939 |
$0.00 |
| 80348 |
|
81 |
65 |
$0.00 |
| 80360 |
|
81 |
65 |
$0.00 |
| 80372 |
|
83 |
67 |
$0.00 |
| 83992 |
|
81 |
65 |
$0.00 |
| G9500 |
Radiation exposure indices documented in final report for procedure using fluoroscopy |
205 |
105 |
$0.00 |
| 80362 |
|
81 |
65 |
$0.00 |
| 80356 |
|
81 |
65 |
$0.00 |
| 80369 |
|
81 |
65 |
$0.00 |
| 1036F |
|
3,237 |
2,843 |
$0.00 |
| 80371 |
|
81 |
65 |
$0.00 |
| 80363 |
|
80 |
64 |
$0.00 |
| 1123F |
|
49 |
39 |
$0.00 |
| 80358 |
|
81 |
66 |
$0.00 |
| 80352 |
|
77 |
64 |
$0.00 |
| 80359 |
|
81 |
65 |
$0.00 |
| 80335 |
|
81 |
65 |
$0.00 |
| 80357 |
|
80 |
64 |
$0.00 |
| G9585 |
Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy |
14 |
12 |
$0.00 |